Prostate Cancer
Drug combination slows progression of aggressive prostate cancer
A phase III trial has shown that adding niraparib to standard prostate cancer therapy significantly delays disease progression in men with specific DNA repair gene mutations. The AMPLITUDE study, involving 696 men across 32 countries, reported a 37% reduced risk of cancer growth overall and 48% in BRCA-mutated cases. This marks a step toward precision medicine for advanced prostate cancer.
Drug combo cuts prostate cancer death risk by over 40 percent
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
AI tool predicts prostate cancer recurrence after radiation
Researchers unveiled an AI model at the ASTRO Annual Meeting that accurately predicts biochemical recurrence in prostate cancer patients following radiation therapy. The tool uses pre-treatment MRI scans and clinical data to outperform traditional risk models. This advancement could help tailor treatments more effectively.